Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Sulfatinib T capsule
Sulfatinib T · 1 trial · 1 indication
The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.
Maximum observed concentration, occurring at Tmax.
The time at which maximum plasma concentration (Cmax) is observed.
The time required for the concentration of the drug to reach half of its original value.
This term represents the relationship between the bioavailability of a substance in two different media.
| Arm | Type | Description |
|---|---|---|
| Arm A-Sulfatinib T capsule | EXPERIMENTAL | The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. |
| Arm B-Sulfatinib R capsule | EXPERIMENTAL | The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd. |
| Name | Type | Description |
|---|---|---|
| Sulfatinib T capsule | DRUG | Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production. |
| Sulfatinib R capsule | DRUG | Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd. |
Inclusion Criteria: 1. Subjects must be voluntary and sign an informed consent form and agree to comply with the requirements of the protocol； 2. Age of 18-40 (inclusive), male healthy volunteers； 3. Medical history, physical examination, 12-lead ECG and laboratory tests at screening judged as norm...
Sulfatinib T is an investigational small molecule drug developed by HUTCHMED (China) Limited. It is a kinase inhibitor belonging to the -tinib class. It has been studied in a Phase 1 clinical trial in China. Sulfatinib T is also known as Sulfatinib T capsule.
Sulfatinib T is a kinase inhibitor, meaning it targets kinases, which are enzymes that regulate cell signaling. As a small molecule in the -tinib class, it is designed to inhibit kinase activity. The specific kinase targets have not been disclosed.
Sulfatinib T is developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the Nasdaq under the ticker HCM. HUTCHMED is responsible for the research and clinical development of Sulfatinib T.
Sulfatinib T is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any regulatory agency. The Phase 1 trial has been completed.
Sulfatinib T has been evaluated in one completed Phase 1 clinical trial, NCT03483259, titled "To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers." The trial enrolled 30 male participants in China and was controlled but not double-blind.
Yes, Sulfatinib T capsule is an alternative name for Sulfatinib T. Both refer to the same investigational drug developed by HUTCHMED (China) Limited.